EDITORIAL

 

Prevention of hepatocellular carcinoma

 

 

M. C. Kew

Department of Medicine, University of Cape Town and Groote Schuur Hospital Cape Town, and Department of Medicine University of the Witwatersrand Johannesburg

 

 

“Full text available only in PDF format”

 

REFERENCES

1. Ferlay J, Shin HR, Bray F, et al. Establishment of world-wide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.         [ Links ]

2. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.         [ Links ]

3. Kew MC. Epidemiology of hepatitis B virus, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris) 2010;58:273-277.         [ Links ]

4. Beasely RP, Wang LY, Chin CC, et al. Hepatocellular carcinoma and HBV: A prospective study of 22,707 men in Taiwan. Lancet 1981;22:1129-1133.         [ Links ]

5. Chang MH, You SL, Chen CJH, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B virus vaccinees: a 20 year follow-up. J Natl Cancer Inst 2009;101:1348-1355.         [ Links ]

6. Kew MC. Hepatitis C and hepatocellular carcinoma in developing and developed countries. Viral Hepatitis Reviews 1998;4:259-269.         [ Links ]

7. World Health Organization Hepatitis B Fact Sheet. No. 204 (revised October 2000). https://apps.who.int/inf-fs/en/fact204.html (accessed 7 March 2011).         [ Links ]

8. Kew MC, Francois G, Lavanchy D, et al. Prevention of hepatitis C virus infection. J Viral Hepatit 2004;11:198-205.         [ Links ]

9. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23:1-5.         [ Links ]

10. Turner PC, Sylla A, Gong YY, et al. Reduction in exposure to carcinogenic anatoxins by post-harvest intervention measures in west Africa: a community-based intervention study. Lancet 2005;365:1950-1956.         [ Links ]

11. Egner PA, Wang JN, Zu YR, et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk of liver cancer. Proc Natl Acad Sci USA 2001; 98:14601-14606.         [ Links ]

12. Sudaken DL. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J Toxicol Clin Toxicol 2003;41:195-204.         [ Links ]

13. Sofowora GG,Choo EF, Mayo G, et al. In vivo inhibition of human CYPA2 activity by oltipraz. Cancer Chemother Pharmacol 2001;47:505-509.         [ Links ]

14. Niederau C, Fischer R. Sonnenberg A, et al. Survival and causes of death in cirrhotic and non-cirrhotic patients with hereditary hemochromatosis. N Engl J Med 1985;313:1256-1262.         [ Links ]

15. Mandishona E, MacPhail AP, Gordeuk VR, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans. Hepatology 1998;27:1563-1566.         [ Links ]

16. Gordeuk VR. African iron overload. Semin Haematol 2002;39:263-269.         [ Links ]

17. Asare GA, Bronze M, Naidoo V, et al. Interaction between aflatoxin B1 and dietary iron overload in hepatic mutagenesis. Toxicology 2007;234:157-166.         [ Links ]

18. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma. Cancer 2009;115:5651-5661.         [ Links ]